Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Schering Antifungal "Free" Offers Not Exempt From FTC Rules - NAD

This article was originally published in The Tan Sheet

Executive Summary

Schering-Plough's year-round offers of "bonus" sizes of Lotrimin AF and Tinactin topical antifungal products are not exempt from Federal Trade Commission rules regarding the timing of "free" offers, the National Advertising Division of the Council of Better Business Bureaus concludes in its January case report.

You may also be interested in...

Schering, Playtex Agree To Bring Suncare Ads In Line With FTC Guide

Schering-Plough and Playtex should modify product advertising claiming "free" bonus amounts to facilitate third-party evaluation of such promotions, NAD states in its February Case Reports.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts